Sightera Biosciences
AI drug discovery startup that learns directly from patient biology to identify and design novel medicines, focusing on oncology and fibrosis.
About
Sightera Biosciences is a biotechnology company focused on AI-driven drug discovery. It differentiates itself by training its AI models on proprietary data derived directly from patient-derived biological material, particularly from patients with advanced, therapy-resistant, or end-staged diseases. The company aims to accelerate the development of novel therapies by designing small molecules based on biological responses observed in patient-derived systems, rather than chemical properties alone. Teams look it up for Biotechnology, Artificial Intelligence, Drug Discovery.
Frequently asked
What does Sightera Biosciences do?
Sightera Biosciences is a Biotechnology company that offers Platform. Teams look it up for Artificial Intelligence, Drug Discovery, Oncology. It is based in Antwerp, Belgium and was founded in 2025. Public records show $3M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Sightera Biosciences raised?
Sightera Biosciences has raised a total of $3M in funding. The most recent round on record is Pre-Seed.
Where is Sightera Biosciences headquartered?
Sightera Biosciences is headquartered in Antwerp, Belgium.
When was Sightera Biosciences founded?
Sightera Biosciences was founded in 2025.
What industry does Sightera Biosciences operate in?
Sightera Biosciences operates in Biotechnology, Artificial Intelligence, Drug Discovery, Oncology, Fibrosis.
What is Sightera Biosciences's current status?
Sightera Biosciences's current operating status is: Inactive.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.